Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM82Y75)

Drug Name
PIRINIXIC ACID Drug Info
Synonyms
Pirinixic acid; 50892-23-4; WY-14643; [4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid; WY-14,643; WY14643; Wyeth 14,643; Wy 14643; Pirinixic acid [INN]; WY-14643 (Pirinixic Acid); (4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio)acetic acid; UNII-86C4MRT55A; C14H14ClN3O2S; CCRIS 133; Acidum pirinixicum [INN-Latin]; Acide pirinixique [INN-French]; Acido pirinixico [INN-Spanish]; NSC310038; NSC-310038; NSC 310038; BRN 0759945; ((4-Chloro-6-((2,3-dimethylphenyl)amino)-2-pyrimidinyl)thio)acetic acid; Acetic acid, ((4-chloro-6-(
Cross-matching ID
PubChem CID
5694
ChEBI ID
CHEMBL295416
CAS Number
CAS 50892-23-4
TTD Drug ID
D09XCX

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Asthma 1.95 3.15e-2 25/31 (80.65%) CD40;HLA-DRB1;HLA-DRA;...
DNA replication 1.84 3.54e-2 34/36 (94.44%) RNASEH2A;MCM7;POLD2;...
Spliceosome 1.84 2.62e-2 101/150 (67.33%) HSPA2;LSM8;RBMX;...
Nitrogen metabolism 1.78 3.93e-2 16/17 (94.12%) CA2;CA12;GLUL;...
Base excision repair 1.78 3.15e-2 29/33 (87.88%) APEX1;PARP2;POLD2;...
Allograft rejection 1.73 4.33e-2 32/38 (84.21%) CD40;HLA-DRB1;HLA-DRA;...
Intestinal immune network for IgA production 1.72 3.93e-2 38/48 (79.17%) CD40;CXCL12;HLA-DRB1;...
Systemic lupus erythematosus 1.70 4.52e-2 45/135 (33.33%) CD40;HLA-DRB1;HLA-DRA;...
Primary immunodeficiency 1.70 4.02e-2 33/38 (86.84%) BLNK;CD40;BTK;...
Mismatch repair 1.70 3.62e-2 22/23 (95.65%) EXO1;POLD2;MSH6;...
Ascorbate and aldarate metabolism 1.67 4.43e-2 15/30 (50%) ALDH2;UGT2B28;UGT2B15;...
Cortisol synthesis and secretion -1.87 4.80e-2 58/65 (89.23%) PDE8B;CYP11A1;SCARB1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 1.25uM - 40uM 3H, 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H